利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.029 秒)

    Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent
    2.
    发明申请
    Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent 审中-公开
    阿利吉仑作为高血压药物的功效生物标志物

    公开(公告)号：US20100240760A1

    公开(公告)日：2010-09-23

    申请号：US11909202

    申请日：2006-03-20

    申请人： Jessie Gu ,  Joanne Meyer

    发明人： Jessie Gu ,  Joanne Meyer

    IPC分类号： A61K31/165 ,  C12Q1/68 ,  A61P9/12

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： A retrospective pharmacogenetic analysis was conducted in an attempt to evaluate potential association between genetic variation and outcome of a clinical trial of efficacy of aliskiren as an antihypertensive agent. Forty-eight polymorphisms were examined in twelve genes from the renin-angiotensin-aldosterone system (RAS) or previously implicated in blood pressure regulation. Significant associations were seen between one polymorphism in the angiotensin converting enzyme (ACE) gene, two polymorphisms in the angiotensin II type 2 receptor (AGTR2) gene, and clinical parameters of mean sitting diastolic and systolic blood pressure decrease. These effects were not found with irbesartan and placebo treatment, but instead were specific to aliskiren treatment.

    摘要翻译： 进行回顾性药物遗传分析以试图评估阿利吉仑作为抗高血压药物的效力的临床试验的遗传变异与结果之间的潜在联系。 在来自肾素 - 血管紧张素 - 醛固酮系统（RAS）的12个基因或之前涉及血压调节中检查了48个多态性。 血管紧张素转换酶（ACE）基因的一个多态性，血管紧张素II 2型受体（AGTR2）基因中的两个多态性和平均舒张压和收缩压降低的临床参数之间有显着的关联。 厄贝沙坦和安慰剂治疗未发现这些作用，而是特异于阿利吉仑治疗。

    Use of Organic Compound for the Treatment of Noonan Syndrome
    4.
    发明申请
    Use of Organic Compound for the Treatment of Noonan Syndrome 有权
    使用有机化合物治疗Noonan综合征

    公开(公告)号：US20140200249A1

    公开(公告)日：2014-07-17

    申请号：US14239165

    申请日：2012-08-29

    申请人： Jessie Gu

    发明人： Jessie Gu

    IPC分类号： C07D235/08

    CPC分类号： A61K31/4184 ,  A61K31/416 ,  C07D235/08

    摘要： The use of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Noonan Syndrome, a method of treating a warm-blooded animal, especially a human, having Noonan Syndrome, comprising administering to said animal a therapeutically effective amount of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof; and to a pharmaceutical composition and a commercial package comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a package insert or other labeling including directions for treating Noonan Syndrome.

    摘要翻译： 使用如本文所定义的式（I）的MEK抑制剂化合物或其药学上可接受的盐在制备用于治疗Noonan综合征的药物中的用途，一种治疗温血动物，特别是人的方法， 包括向所述动物施用治疗有效量的如本文定义的式（I）的MEK抑制剂化合物或其药学上可接受的盐; 以及包含式（I）化合物或其药学上可接受的盐的药物组合物和商业包装，以及包括治疗Noonan综合征的指示的包装插页或其他标签。

    Use of organic compound for the treatment of Noonan Syndrome
    6.
    发明授权
    Use of organic compound for the treatment of Noonan Syndrome 有权
    使用有机化合物治疗Noonan综合征

    公开(公告)号：US09034909B2

    公开(公告)日：2015-05-19

    申请号：US14239165

    申请日：2012-08-29

    申请人： Jessie Gu

    发明人： Jessie Gu

    IPC分类号： A61K31/4184 ,  C07D235/08 ,  A61K31/416

    CPC分类号： A61K31/4184 ,  A61K31/416 ,  C07D235/08

    摘要： The use of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Noonan Syndrome, a method of treating a warm-blooded animal, especially a human, having Noonan Syndrome, comprising administering to said animal a therapeutically effective amount of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof; and to a pharmaceutical composition and a commercial package comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a package insert or other labeling including directions for treating Noonan Syndrome.

    摘要翻译： 使用如本文所定义的式（I）的MEK抑制剂化合物或其药学上可接受的盐在制备用于治疗Noonan综合征的药物中的用途，一种治疗温血动物，特别是人的方法， 包括向所述动物施用治疗有效量的如本文定义的式（I）的MEK抑制剂化合物或其药学上可接受的盐; 以及包含式（I）化合物或其药学上可接受的盐的药物组合物和商业包装，以及包括治疗Noonan综合征的指示的包装插页或其他标签。